In this video, Charu Aggarwal, MD, MPH, the Leslye M. Heisler Professor for Lung Cancer Excellence at University of ...

New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relacorilant plus nab-paclitaxel showed a PFS benefit in patients with ...

Immune checkpoint inhibitors have shown efficacy in other HPV-related cancers, so a phase 2 trial tested avelumab treatment for locally advanced or metastatic penile cancer.

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% ...

Incyte (Nasdaq:INCY) today reported financial results for the third quarter of 2025 and provided a business update.

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...

NovoCure Ltd. (($NVCR)) announced an update on their ongoing clinical study. The LUNAR-2 study by NovoCure Ltd. aims to evaluate the effectiveness ...

Genelux Corp. (($GNLX)) announced an update on their ongoing clinical study. Genelux Corp. is currently conducting a Phase 2 clinical study titled ...

The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.

Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

“The results of our analysis showed that overall, patients with SCLC who survived to receive 3L treatment are a select group ...

Results showed a 77% survival rate in patients below 50 years who used carboplatin, an increase from the 66% without it | ...